Related Experiment Videos
Retinal vein occlusions in patients taking warfarin
David J Browning1, Christina M Fraser
1Charlotte Eye, Ear, Nose, and Throat Associates, Charlotte, North Carolina, USA. dbrowning@ceenta.com
Ophthalmology
|June 5, 2004
Summary
Warfarin anticoagulation does not prevent retinal vein occlusion (RVO) in susceptible individuals. Maintaining an international normalized ratio (INR) above 2.0 may reduce RVO risk in patients on warfarin.
Area of Science:
- Ophthalmology
- Hematology
- Vascular Medicine
Background:
- Retinal vein occlusion (RVO) is a significant cause of vision loss.
- Warfarin is commonly prescribed for anticoagulation to prevent thromboembolic events.
- The risk of RVO in patients treated with warfarin is not well-established.
Observation:
- A retrospective case series of 13 patients who developed RVO while on warfarin therapy.
- Patients had varying international normalized ratio (INR) levels at the time of RVO, with 9 of 13 below 2.0.
- Concurrent use of acetylsalicylic acid and underlying conditions like hypertension or lupus anticoagulant were noted in some patients.
Findings:
- Warfarin anticoagulation did not preclude the development of RVO in this cohort.
- RVO occurred even with INRs within the therapeutic range for some patients.
- Combination therapy with warfarin and aspirin did not prevent RVO.
Implications:
- Warfarin therapy alone does not guarantee protection against RVO.
- Careful monitoring and potentially higher INR targets (>2.0) might be beneficial in predisposed individuals.
- Further research is needed to elucidate the precise role of anticoagulation intensity in RVO development.